Frank Amato is CEO and President of SYNAPS Dx. Previously, after two decades in the pharmaceutical and biotech industries he was President, CEO, and Director of electroCore, a NASDAQ-traded bioelectronic medicine company focused on treating neurological conditions. Frank is an accomplished leader with a track record of consistently delivering strong results. Prior to his tenure at electroCore, Frank was Vice President of the Specialty Commercial Operations Group at Merck, which comprised 9 specialty therapeutic divisions. He had responsibility for leading approximately 2,000 employees, generating $4.5b in annual revenue across 16 different pharmaceutical products. After Merck’s acquisition of Schering-Plough, he led the integration of approximately 3,000 employees into the new company. In addition to his day-to-day business responsibilities, Amato was accountable for various aspects of due diligence, negotiation, integration, and launching products in neuroscience, virology, and ophthalmology.

After serving as an infantry field medic in the 82nd Airborne Division, US Army, Frank began his career as a sales professional in New York City with the Upjohn Company. Throughout his career, Frank has worked on key initiatives in the US, Europe, and Japan, managing teams of senior executives in sales, marketing, operations, finance, legal, medical, regulatory, and research and development. He received his bachelor’s degree in Political Science with a minor in Theology from St. John’s University and MBA from Pepperdine University.